Cortexyme, Inc., a South San Francisco, CA-based clinical-stage pharmaceutical company developing therapeutics to alter the course of Alzheimer’s disease (AD) and other degenerative diseases, completed a $76m Series B financing.
Backers included new investors Sequoia Capital, Vulcan Capital, Verily Life Sciences, EPIQ Capital Group, RSL Investments, Huizenga Capital, and one of the world’s largest long-term mutual funds, and current investors Pfizer, Takeda Ventures, Lamond Family, Breakout Ventures, and Dolby Family Ventures.
The company will use the funds to continue to expand its development efforts.
Led by Casey Lynch, co-founder and chief executive officer, and Stephen Dominy, M.D., co-founder and chief scientific officer, Cortexyme is a clinical-stage pharmaceutical company developing therapeutics to alter the course of Alzheimer’s and other degenerative disorders.
The lead compound, COR388, an orally administered bacterial protease inhibitor that targets a specific pathogen discovered in the brains of patients with Alzheimer’s, is the subject of an ongoing phase 1 clinical development program. Additional proprietary small molecules are moving forward in preclinical development.